Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.
1 . A method for improving cognition comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, at a daily dose of less than 3 mg.
2 . The method of claim 1 wherein the daily dose is 1 mg or less.
3 . The method of claim 2 wherein the daily dose is 0.3 mg or less.
4 . A method for treating a cognitive disorder comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, at a daily dose of less than 3 mg.
5 . The method of claim 4 wherein the daily dose is 1 mg or less.
6 . The method of claim 5 wherein the daily dose is 0.3 mg or less.
7 . A method for treating a disorder selected from schizophrenia, schizophreniform disorder, schizoaffective disorder, and delusional disorder, comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, at a daily dose of less than 3 mg.
8 . The method of claim 7 wherein the daily dose is 1 mg or less.
9 . The method of claim 8 wherein the daily dose is 0.3 mg or less
10 . A method for improving one or more of: learning, delayed memory, working memory, visual learning, speed of processing, vigilance, verbal learning, visual motor function, social cognition, long term memory or executive function, comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, at a daily dose of less than 3 mg.
11 . The method of claim 10 wherein the daily dose is 1 mg or less.
12 . The method of claim 11 wherein the daily dose is 0.3 mg or less.
13 . A method for improving executive function comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, at a daily dose of less than 3 mg.
14 . The method of claim 13 wherein the daily dose is 1 mg or less.
15 . The method of claim 14 wherein the daily dose is 0.3 mg or less.
16 . A method for treating one or more symptoms of Alzheimer's disease comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, at a daily dose of less than 3 mg.
17 . The method of claim 16 wherein the daily dose is 1 mg or less.
18 . The method of claim 17 wherein the daily dose is 0.3 mg or less.
19 . A method for improving one or more of: visual motor skills, learning, executive function and delayed memory in a subject, the method comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, at a daily dose of less than 3 mg.
20 . The method of claim 19 wherein the daily dose is 1 mg or less.
21 . The method of claim 20 wherein the daily dose is 0.3 mg or less.
22 . A method for improving one or more of: attention, learning, delayed memory, working memory, visual learning, speed of processing, vigilance, verbal learning, visual motor function, social cognition, long term memory or executive function, comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, at a daily dose of less than 3 mg.
23 . The method of claim 22 wherein the daily dose is 1 mg or less.
24 . The method of claim 23 wherein the daily dose is 0.3 mg or less.
25 . The method of any of the forgoing claims wherein the subject is suffering from anxiety or agitation.
26 . A unit dose pharmaceutical composition comprising 0.3 to 3.0 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
27 . A unit dose pharmaceutical composition comprising 0.3 to 1.5 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
28 . A unit dose pharmaceutical composition comprising 1.0 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.